Full-Time

Oncology Account Specialist Western Canada

Oncology, Rare Disease

Posted on 10/4/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

No salary listed

Vancouver, BC, Canada

In Person

Field-based role; approximately 50% overnight travel; Western Canada territory.

Category
Sales & Account Management (2)
,
Required Skills
Sales
Data Analysis
Requirements
  • Bachelor’s degree in science or business required
  • Five years of pharmaceutical sales experience with a minimum of three years of pharmaceutical account management experience
  • Three years’ experience within institutional, oncology, or rare disease sales
  • Proven track record of sales success with the ability to successfully develop and apply clinical and business expertise, and effective selling skills
  • Ability to discuss therapeutic strategies to inform and influence decision-makers
  • Possesses a strong track record of maintaining therapeutic area/product knowledge
  • Knowledge of applicable federal and provincial regulations affecting the pharmaceutical industry, as well as the Innovative Medicines Canada (IMC) Code of Ethical Practices
  • Proficient in MS Office
  • Excellent organizational/communication skills, initiative, and ambition to succeed are all essential
  • Ability to lead without authority
  • Demonstrated ability to organize, prioritize, meet deadlines, make decisions, and change course of action quickly
  • Strong interpersonal and communication skills
  • A strong work ethic is required
  • Detail-oriented and excellent follow-through
  • Has the ability to flex and deal with ambiguity in a dynamic, fast-paced, high-growth environment
  • Has a passion for personal learning and development to be able to grow with the company
  • Cultural sensitivity and ability to develop consensus within a multinational organization
Responsibilities
  • Drive effective Cancer Care Centers planning and management process for target hospital systems, the patient journey for that system, identifying key influences within the Cancer Care Centers, and building relationships to drive sales
  • Develop and maintain a deep understanding of the oncology and dermatology centers in assigned regions, identifying and mapping key stakeholders and patient flows
  • Understands and applies knowledge of the healthcare industry, trends, market conditions, and market access environment within the Oncology and Dermatology market space, including but not limited to pharmacy-economics, and payer/reimbursement landscape
  • Review and analyze product performance within Cancer Care Centers and take and/or evolve actions as appropriately
  • Conduct day-to-day Health Care Professional and Cancer Care Center interactions conveying complex, approved, promotional information fluently in a professional, compliant, ethical, and effective manner
  • Educate referral networks and co-management networks on disease best practices
  • Analyze patient flow/between institutions and community practices in the development of business plans and the daily execution of sales calls
  • Demonstrate a strong understanding of current or pending clinical pathways within an institution and map patient flow/influence between institutions
  • By providing the appropriate knowledge and information on the product, it enables the Care Team to identify and track potential patients for follow-up with HCP
  • Ensure maintenance on the product by supporting appropriate multidisciplinary Health Care Professionals (Hematologist-Oncologists, Dermatologists, Radiation Oncologists, Pathologists, Nurses, Pharmacists, etc.) support of the patients via their care network
  • Collaborate cross-functionally with internal/external customers to develop and implement actionable business plans that drive any formularies and protocols/pathways additions that are required to drive sales volume within Cancer Care Centers
  • Demonstrated highly effective Cancer Care Center management skills and exemplary selling competencies
  • Maintain knowledge of Oncology and Rare Disease standards of care and emerging clinical trends, and can articulate approved, on-label product information related to these topics

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE